General Partner, OrbiMed Advisors

Mona Ashiya is a General Partner on the private equity team at OrbiMed. Prior to OrbiMed, she covered the biotechnology industry as a member of J.P. Morgan’s biotechnology equity research team. Mona co-founded Prevail Therapeutics. Her previous experience includes positions at the Global Alliance for TB Drug Development and the Harvard Business School. She has also published scientific articles in various peer reviewed journals. She earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute where her research focused on mechanisms of programmed cell death.